@article{oai:repo.qst.go.jp:00058796,
 author = {安永正浩 and 眞鍋史乃 and 辻, 厚至 and 古田大 and 緒方是嗣 and 古賀宣勝 and 藤原悠起 and 佐賀恒夫 and 松村保広 and 辻 厚至},
 issue = {5},
 journal = {YAKUGAKU ZASSHI},
 month = {May},
 note = {Antibodydrug conjugates (ADCs) comprise an antibody, a linker, and a drug or payload. The selection of a
tumor-speciˆc antibody and development of a linker having an e‹cient controlled drug release (CDR) are critical steps
in developing a fully functional and eŠective ADC. In our research strategy, molecular imaging technologies have been
employed to evaluate the e‹ciency of antibody delivery and CDR of the linker. In preclinical setting, antibody delivery
into the tumor area or antibody penetration through the tumor stroma in malignant lymphoma or pancreatic tumor was
evaluated by in vivo ‰uorescence imaging technique. Positron emission tomography (PET) imaging studies were conducted
using 89Zr-labeled antibody to evaluate tumor targeting in a spontaneous carcinogenesis model. The model had
dense stroma and was pathophysiologically very similar to human cancer. The drug imaging system, using microscopic
mass spectroscopy (MMS) with enhanced resolution and sensitivity, was used for the evaluation of CDR. Paclitaxel
(PTX)-incorporated micelle, a high-molecular-weight (HMW) carrier with CDR, showing similar properties as those
of ADC, was analyzed. In contrast to free PTX, micelle selectively increased drug accumulation into the tumor and
reduced toxicity in normal tissues by the enhanced permeability and retention (EPR) eŠect. Our drug imaging system
has been used recently to evaluate the CDR of the ADC-linker.We present our work on the development of ADC using amolecular imaging technique.},
 pages = {535--544},
 title = {分子イメージングを駆使したADC の開発},
 volume = {137},
 year = {2017}
}